benzyl ((3-phenylpropionyl)oxy)carbamate | 1257267-04-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl ((3-phenylpropionyl)oxy)carbamate
• 英文别名: Phenylmethoxycarbonylamino 3-phenylpropanoate
• CAS: 1257267-04-1
• 化学式: C₁₇H₁₇NO₄
• 分子量: 299.326
• InChiKey: KUFKTNPJTKQBOJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  benzyl ((3-phenylpropionyl)oxy)carbamate 反应 1.0h， 以79%的产率得到benzyl (2-phenylethyl)carbamate
  参考文献：
  名称：

  一种碱催化的脱羧胺化制备胺类化合物的方法

  摘要：

  本发明公开了一种碱催化的由羧酸或或羧酸衍生物(酯)制备胺类化合物的方法，所述方法为烷基、芳基或杂环芳香羧酸或酯与羟胺类化合物反应得到酰氧基氨基甲酸酯中间体，在碱的作用下发生脱羧胺化反应从而得到胺类化合物。与传统的同类反应如Curtis重排、Lossen重排反应相比，本方法操作简便，反应条件温和，底物更加稳定，原子利用率高，副产物仅为二氧化碳无污染，并且产率可达到90％，适合产业化生产。

  公开号：

  CN110878034A
• 作为产物：
  描述：

  氯甲酸苄酯 在 盐酸羟胺 、 N,N'-二环己基碳二亚胺 、 sodium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 2.5h， 生成 benzyl ((3-phenylpropionyl)oxy)carbamate
  参考文献：
  名称：

  Base-Mediated Intramolecular Decarboxylative Synthesis of Alkylamines from Alkanoyloxycarbamates

  摘要：

  A general and effective method for the synthesis of alkylamine via intramolecular decarboxylation of alkanoyloxycarbamates is described. The alkanoyloxycarbamates are readily prepared with alkyl carboxylic acids and hydroxylamine. The reaction shows a broad range of substrates (primary and secondary alkyl) with functional tolerance, and the corresponding products were obtained in good yields under mild conditions.

  DOI：

  10.1021/acs.joc.8b00970

文献信息

• Serendipitous Discovery of α-Hydroxyalkyl Esters as β-Lactamase Substrates
  作者：Ryan B. Pelto、R. F. Pratt

  DOI：10.1021/bi101071r

  日期：2010.12.14

  O-(1-Carboxy-1-alkyloxycarbonyl) hydroxamates were found to spontaneously decarboxylate in aqueous neutral buffer to form O-(2-hydroxyalkylcarbonyl) hydroxamates, While the former molecules do not react rapidly with serine beta-lactamases, the latter are quite good substrates of representative class A and C, but not D, enzymes, and particularly of a class C enzyme. The enzymes catalyze hydrolysis of these compounds to a mixture of the alpha-hydroxy acid and hydroxamate. Analogous compounds containing aryloxy leaving groups rather that hydroxamates are also substrates. Structure-activity experiments showed that the alpha-hydroxyl group was required for any substantial substrate activity. Although both D- and L-alpha-hydroxy acid derivatives were substrates, the former were preferred. The response of the class C activity to pH and to alternative nucleophiles (methanol and D-phenylalanine) suggested that the same active site functional groups participated in catalysis as for classical substrates. Molecular modeling was employed to explore how the alpha-hydroxy group might interact with the class C beta-lactamase active site. Incorporation of the alpha-hydroxyalkyl moiety into novel inhibitors will be of considerable interest.
• SPIROIMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1183241A1

  公开（公告）日：2002-03-06
• US6294562B1
  申请人：——

  公开号：US6294562B1

  公开（公告）日：2001-09-25
• US6399643B1
  申请人：——

  公开号：US6399643B1

  公开（公告）日：2002-06-04
• [EN] SPIROIMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM<br/>[FR] DERIVES DE SPIROIMIDAZOLIDINE, PREPARATION ET UTILISATION DE CES DERIVES ET PREPARATION PHARMACEUTIQUES A BASE DE CES DERIVES.
  申请人：AVENTIS PHARMA GMBH

  公开号：WO2000069831A1

  公开（公告）日：2000-11-23

  The present invention relates to spiroimidazolidine derivatives of formula (I) in which E, V, W, X, R?1 and R2¿ have the meanings indicated in the claims. The compounds of formula (I) are valuable pharmaceutical active compounds which are suitable, for example, for the therapy and prophylaxis of inflammatory disorders, for example of rheumatoid arthritis, or of allergic disorders. The compounds of formula (I) are inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy and prophylaxis of illnesses which are caused by an undesired extent of leukocyte adhesion and/or leukocyte migration or are associated therewith or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part. The invention furthermore relates to processes for the preparation of the compounds of formula (I), their use and pharmaceutical preparations which contain compounds of formula (I).